Acute myeloid leukemia: current progress and future directions

Research output: Contribution to journalReview articlepeer-review

Abstract

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.

Original languageEnglish (US)
Article number41
JournalBlood cancer journal
Volume11
Issue number2
DOIs
StatePublished - Feb 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Acute myeloid leukemia: current progress and future directions'. Together they form a unique fingerprint.

Cite this